Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132721) titled 'A Randomized Phase II Study of Lisaftoclax Combined with IA (2+5) Regimen versus Standard "3+7" Chemotherapy in Fit Patients with Treatment-Naive Acute Myeloid Leukemia' on Sept. 17.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Wenzhou Medical University
Condition:
Acute myeloid leukemia
Intervention:
Control arm:standard "3+7" regimen
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-01
Target Sample Size: Control arm:24;Experimental arm:49;
Countries of Recruitment:
China
To know more, visit https://www.ch...